315 related articles for article (PubMed ID: 29076344)
1. Exploration of Zinc Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer Nanomedicine.
Wang J; Lee JS; Kim D; Zhu L
ACS Appl Mater Interfaces; 2017 Nov; 9(46):39971-39984. PubMed ID: 29076344
[TBL] [Abstract][Full Text] [Related]
2. The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.
Deng Y; Zhang H
Int J Nanomedicine; 2013; 8():1835-41. PubMed ID: 23674895
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of doxorubicin modified ZnO/PEG nanomaterials and its photodynamic action.
Hariharan R; Senthilkumar S; Suganthi A; Rajarajan M
J Photochem Photobiol B; 2012 Nov; 116():56-65. PubMed ID: 22982207
[TBL] [Abstract][Full Text] [Related]
5. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death.
Zhang Y; Guo C; Liu L; Xu J; Jiang H; Li D; Lan J; Li J; Yang J; Tu Q; Sun X; Alamgir M; Chen X; Shen G; Zhu J; Tao J
Theranostics; 2020; 10(24):11197-11214. PubMed ID: 33042278
[No Abstract] [Full Text] [Related]
6. ZnO-Based Nanoplatforms for Labeling and Treatment of Mouse Tumors without Detectable Toxic Side Effects.
Ye DX; Ma YY; Zhao W; Cao HM; Kong JL; Xiong HM; Möhwald H
ACS Nano; 2016 Apr; 10(4):4294-300. PubMed ID: 27018822
[TBL] [Abstract][Full Text] [Related]
7. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
8. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex
Li Z; Zhang S; Liu M; Zhong T; Li H; Wang J; Zhao H; Tian Y; Wang H; Wang J; Xu M; Wang S; Zhang X
Mol Pharm; 2022 Nov; 19(11):4179-4190. PubMed ID: 36223494
[TBL] [Abstract][Full Text] [Related]
10. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of chemo-photothermal for breast cancer therapy using folic acid (FA) modified zinc oxide nanosheet.
Vimala K; Shanthi K; Sundarraj S; Kannan S
J Colloid Interface Sci; 2017 Feb; 488():92-108. PubMed ID: 27821343
[TBL] [Abstract][Full Text] [Related]
12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
13. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
14. Development and DoE-ANN based optimization of novel swellable matrix-diffusible doxorubicin loaded zinc oxide nanoflowers using sonochemical-precipitation method.
Ijaz S; Sultana M; Shamim R; Bukhari NI
Int J Pharm; 2023 Feb; 633():122584. PubMed ID: 36621704
[TBL] [Abstract][Full Text] [Related]
15. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
18. A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity.
Deng L; Dong H; Dong A; Zhang J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):107-17. PubMed ID: 26515259
[TBL] [Abstract][Full Text] [Related]
19. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery.
Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A
Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767
[TBL] [Abstract][Full Text] [Related]
20. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
